Clinical Trial Limits Must Be Acknowledged In ADR Debate - FDA's Lumpkin
Executive Summary
Reform of the pharmaceutical adverse event monitoring system must be based on a larger debate over the societal expectations for clinical research, Center for Drug Evaluation & Research Deputy Director Murray Lumpkin, MD, told a Drug Information Association/ General Accounting Office panel Feb. 24 in Washington, D.C.
You may also be interested in...
Rx Error Reduction May Need Reduced Prescriber Autonomy - Woodcock
Stricter prescribing regulations may be one way to reduce the number of preventable adverse drug events, FDA Center for Drug Evaluation & Research Director Janet Woodcock, MD, suggested Nov. 17.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011